Untitled

Access the recording.

Download a copy of this content.

HealthTrust presents…”HIT or Miss: Direct Oral Anticoagulants for Heparin-induced Thrombocytopenia”

Heparin-induced thrombocytopenia (HIT) is a life-threatening complication that may occur after exposure to heparin, resulting in both thrombocytopenia and an increased risk of thrombosis. Management of the acute phase of HIT involves discontinuation of all heparin-containing products and initiation of therapeutic anticoagulation with a parenteral non-heparin anticoagulant. Evidence-based clinical practice guidelines historically supported transitioning from a parenteral anticoagulant to an oral vitamin K antagonist once platelet counts recovered. The presenter will explore the newest guidelines, published in 2018 by the American Society of Hematology, which now suggest that direct oral anticoagulants (DOACs) may be considered as options for both the acute and subacute phases of HIT. DOACs have several features that make them attractive such as their rapid onset of action and lack of immunologic activity with HIT antibodies. The updated guideline recommendations from the American Society of Hematology and the current body of literature surrounding the use of DOACs in HIT will be discussed to allow pharmacists to make informed decisions given a clinical scenario.

Learning Objectives for Pharmacists  |  At the end of this session, participants should be able to:

1. Summarize the pathophysiology, clinical features and five phases of HIT
2. Compare and contrast evidence-based guideline recommendations from the American College of Chest Physicians and the American Society of Hematology on the treatment of HIT
3. Evaluate current primary literature available for the use of DOACs in HIT
4. Recall the mechanism of action and dosing of different DOACs used for HIT

Learning Objectives for Pharmacy Technicians  |  At the end of this session, participants should be able to:

1. Recognize complications associated with the development of HIT
2. Identify the five phases of HIT
3. List the DOACs that have been used in the treatment of HIT

Presenter:

Payal Desai, PharmD  |  PGY-1 Pharmacy Resident  | Atlantic Health System

Target Audience:  Pharmacists & Pharmacy Technicians

Continuing Education Information: 1.0 contact hours approved for Pharmacists and Pharmacist Technicians. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Activity Numbers for this activity are 0863-9999-19-042-L01-P and 0863-9999-19-042-L01-T . The activity will provide 1 hour (.1 CEUs) of continuing education credit to pharmacists and pharmacy techs who attend the webinar and complete the online evaluation.

Note about CE credit: If you plan to obtain credit, stay until the end of the presentation to receive the verification code you will need to obtain your continuing education credit. A reminder that CE credit is individual. No group credit is available. Each person must register for this session and attend the webinar for 40 minutes or longer in order to receive an email after the event with instructions on how to apply for continuing education credit. Please do not share the code or forward the email you receive to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. Also, please note: If you are joining only by phone, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.

A participant, sponsor, faculty member or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the Belmont COP may contact the Dean of Belmont University College of Pharmacy in writing at david.gregory@belmont.edu. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.